AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net buying: insiders sold $226K and bought $1.4M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$1.2M netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $11.68
- 52-wk high
- $14.15
- High
- $11.72
- 52-wk low
- $9.22
- Low
- $11.51
- Prev close
- $11.61
- Mkt cap
- $129.8M
- Volume
- 138.1K
- Fwd P/E
- 12.5x
- Beta
- 0.73
- P/S
- 0.4x
- P/B
- 0.7x
- Profit margin
- -8.1%
- Op margin
- -5.7%
- ROE
- -12.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about MED filings
Are insiders buying or selling MEDIFAST INC (MED) stock?
Net buying: insiders sold $226K and bought $1.4M of MED stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $226K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Kiai, Parsa (Director), who bought $1.4M. The latest filing was on Oct 1, 2026.
Which members of Congress have traded MED recently?
None. No member of Congress disclosed a MED trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this MED smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What insiders are doing
Buys (2)
- KP
Kiai Parsa
$529K
bought
- KP
Kiai Parsa
$52K
bought
Sells (1)
- CD
Chard Daniel R
$226K
sold
How top traders are positioned
No tracked top-trader positions in MED right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 58.2% above what analysts expected.
Earnings per share
-$0.67 expected
Reports Nov 2, 2026, in 32 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -8.1%
- Forward P/E
- 12.48
- Market cap
- $130M
Valuation
- P/S0.41
- P/B0.68
Quality
- Operating margin-5.7%
- ROE-12.4%
- ROA-4.6%
Growth
- Beta0.73
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace